Filing Flows › Immunocore Holdings (IMCR) › Q2 2026 › vs Q1 2026
Immunocore Holdings (IMCR) Q2 2026 vs Q1 2026 (quarter over quarter)
Immunocore Holdings's revenue rose $9.2M (+9%) from $107M in Q1 2026 to $116M in Q2 2026.
Immunocore Holdings, Q2 2026: revenue $116M (+18% year over year), operating margin -2.6%, net loss $808K, operating cash flow $15.9M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 13.1% | -14.6% | +27.6 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $116M | $107M | $9.2M | +9% |
| Other income, net | $2.5M | $6.0M | −$3.5M | -59% |
| Net loss | $808K | −$13.0M | $13.8M | — |
| Costs & expenses | $119M | $113M | $6.5M | +6% |
| Operating costs | $119M | $99.4M | $19.5M | +20% |
| Income tax | $294K | $301K | −$7K | -2% |
| Cost of revenue | $1.1M | $434K | $654K | +151% |
| Research & development | $73.9M | $61.1M | $12.8M | +21% |
| SG&A | $43.9M | $37.9M | $6.0M | +16% |
| Operating cash sources | $16.7M | −$26.7M | $43.5M | — |
| Depreciation | $1.0M | $948K | $78K | +8% |
| Share-based compensation | $9.4M | $6.3M | $3.1M | +49% |
| Working capital & other | $6.3M | −$34.0M | $40.3M | — |
| Net loss absorbed | $808K | −$13.0M | $13.8M | — |
| Operating cash flow | $15.9M | −$13.8M | $29.7M | — |
| Free cash flow (OCF − capex) | $15.1M | −$15.6M | $30.7M | — |
| Capital expenditures | $786K | $1.8M | −$995K | -56% |
Questions
How much did Immunocore Holdings's revenue grow quarter over quarter in Q2 2026?
Immunocore Holdings's revenue rose $9.2M (+9%) from $107M in Q1 2026 to $116M in Q2 2026.